An update in our ongoing examination of the performance of two recent drug launches from Sanofi (SNY). One is Toujeo, an injectable. The other is Mannkind‘s (MNKD) much hyped, beloved by retail investors, inhaled insulin Afrezza. These two drugs are both for the treatment of diabetes. Sanofi uses the same salesforce, who would be detailing the exact same doctors for both drugs. Can you spot the commercial flop? Remember folks, we are looking for “up and to the right”, we don’t want to see the patient flatlining.
Can Jefferies’ resident Mannkind moron Shaunak Deepak? Just for fun we’ve extended out the Afrezza data for the full 23 weeks it has been on the market. Toujeo has only been on the market for four months as of the last sales update.